EUVIMEDOpdag EUVIMED
Randomisierte kontrollierte StudieOpen access · CC BY 4.0

The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double‐blind, placebo‐controlled, crossover experiment

Will Lawn iD, Katie Trinci, Claire Mokrysz iD, Anna Borissova, Shelan Ofori, Kat Petrilli iD, Michael Bloomfield, Zarah R Haniff, Daniel Hall, Natalia Fernandez-Vinson, Simiao Wang, Amir Englund and 4 more

Addiction · 2023

DOI: 10.1111/add.16154 ↗

At a glance

Randomisierte kontrollierte Studie in Addiction, 2023. Written by Will Lawn and 15 co-authors. Institution: Department of Psychology, Institute of Psychiatry Psychology and Neuroscience, King's College London, London, UK. Major MEDLINE topics: Cannabis, Cannabidiol, Marijuana Smoking, Hallucinogens. Cited 39 times so far (Crossref); 69 references. The full text is freely available (open access, CC BY 4.0). Funded by: Medical Research Council.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Aims Long‐term harms of cannabis may be exacerbated in adolescence, but little is known about the acute effects of cannabis in adolescents. We aimed to (i) compare the acute effects of cannabis in adolescent and adult cannabis users and (ii) determine if cannabidiol (CBD) acutely modulates the effects of delta‐9‐tetrahydocannabinol (THC).

Design

Randomised, double‐blind, placebo‐controlled, crossover experiment. The experiment was registered on ClinicalTrials.gov (NCT04851392).

Setting

Laboratory in London, United Kingdom.

Participants

Twenty‐four adolescents (12 women, 16‐ to 17‐year‐olds) and 24 adults (12 women, 26‐ to 29‐year‐olds) who used cannabis 0.5–3 days/week and were matched on cannabis use frequency (mean = 1.5 days/week).

Intervention

We administered three weight‐adjusted vaporised cannabis flower preparations: ‘THC’ (8 mg THC for 75 kg person); ‘THC + CBD’ (8 mg THC and 24 mg CBD for 75 kg person); and ‘PLA’ (matched placebo).

Measurements

Primary outcomes were (i) subjective ‘feel drug effect’; (ii) verbal episodic memory (delayed prose recall); and (iii) psychotomimetic effect (Psychotomimetic States Inventory).

Findings

Compared with ‘PLA’, ‘THC’ and ‘THC + CBD’ significantly ( P < 0.001) increased ‘feel drug effect’ (mean difference [MD] = 6.3, 95% CI = 5.3–7.2; MD = 6.8, 95% CI = 6.0–7.7), impaired verbal episodic memory (MD = –2.7, 95% CI = −4.1 to −1.4; MD = −2.9, 95% CI = −4.1 to −1.7) and increased psychotomimetic effects (MD = 7.8, 95% CI = 2.8–12.7; MD = 10.8, 95% CI = 6.2–15.4). There was no evidence that adolescents differed from adults in their responses to cannabis (interaction P ≥ 0.4). Bayesian analyses supported equivalent effects of cannabis in adolescents and adults (Bayes factor [BF 01 ] >3). There was no evidence that CBD significantly modulated the acute effects of THC.

Conclusions

Adolescent cannabis users are neither more resilient nor more vulnerable than adult cannabis users to the acute psychotomimetic, verbal memory‐impairing or subjective effects of cannabis. Furthermore, in adolescents and adults, vaporised cannabidiol does not mitigate the acute harms caused by delta‐9‐tetrahydocannabinol.

Subjects

MeSH terms (MEDLINE)

CannabisCannabidiolMarijuana SmokingHallucinogensAdultAdolescentHumansFemaleBayes TheoremDronabinolCannabinoid Receptor AgonistsDouble-Blind MethodCross-Over Studies

Author keywords

CBDTHCadolescencecannabiscognitionmemorypsychosissubjective drug effects

Substances

CannabidiolDronabinolHallucinogensCannabinoid Receptor Agonists

Authors and institutions

  • Department of Psychology, Institute of Psychiatry Psychology and Neuroscience, King's College London, London, UK.
  • Department of Addictions, Institute of Psychiatry Psychology and Neuroscience, King's College London, London, UK.
  • Clinical Psychopharmacology Unit, Clinical Educational and Health Psychology, University College London, London, UK.
  • Department of Neuroimaging, Institute of Psychiatry Psychology and Neuroscience, King's College London, London, UK.
  • NIHR University College London Hospitals Biomedical Research Centre, University College Hospital, London, UK.
  • Addiction and Mental Health Group (AIM), Department of Psychology, University of Bath, Bath, UK.

ORCID profiles: Will Lawn, Claire Mokrysz, Kat Petrilli, Tom P Freeman

Funding

  • Medical Research Council

Cite

APA

Lawn, W., Trinci, K., Mokrysz, C., Borissova, A., Ofori, S., Petrilli, K., Bloomfield, M., Haniff, Z. R., Hall, D., Fernandez-Vinson, N., Wang, S., Englund, A., Chesney, E., Wall, M. B., Freeman, T. P., & Curran, H. V. (2023). The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double‐blind, placebo‐controlled, crossover experiment. Addiction. https://doi.org/10.1111/add.16154

Vancouver

Lawn W, Trinci K, Mokrysz C, Borissova A, Ofori S, Petrilli K, et al. The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double‐blind, placebo‐controlled, crossover experiment. Addiction. 2023. doi:10.1111/add.16154

BibTeX
@article{Lawn2023,
  author = {Lawn, Will and Trinci, Katie and Mokrysz, Claire and Borissova, Anna and Ofori, Shelan and Petrilli, Kat and Bloomfield, Michael and Haniff, Zarah R and Hall, Daniel and Fernandez-Vinson, Natalia and Wang, Simiao and Englund, Amir and Chesney, Edward and Wall, Matthew B and Freeman, Tom P and Curran, H Valerie},
  title = {The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double‐blind, placebo‐controlled, crossover experiment},
  journal = {Addiction},
  year = {2023},
  doi = {10.1111/add.16154}
}
Start for free →